vs
Apellis Pharmaceuticals, Inc.（APLS）与Udemy, Inc.（UDMY）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是Udemy, Inc.的1.0倍（$199.9M vs $194.0M），Udemy, Inc.净利率更高（-1.2% vs -29.5%，领先28.3%），Udemy, Inc.同比增速更快（-3.0% vs -5.9%），Udemy, Inc.自由现金流更多（$15.0M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -0.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Udemy是一家总部位于美国的教育科技企业，2010年成立，最初定位为大规模开放在线课程提供商，目前核心办公地点位于加州旧金山，在美、澳、印、爱、墨、土多国均设有分支机构。它主打在线教育平台，支持用户自主创建并分享课程，平台课程以按需点播的视频内容为主，截至2025年初已拥有数百万个人用户。
APLS vs UDMY — 直观对比
营收规模更大
APLS
是对方的1.0倍
$194.0M
营收增速更快
UDMY
高出3.0%
-5.9%
净利率更高
UDMY
高出28.3%
-29.5%
自由现金流更多
UDMY
多$29.3M
$-14.3M
两年增速更快
APLS
近两年复合增速
-0.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $194.0M |
| 净利润 | $-59.0M | $-2.3M |
| 毛利率 | — | 66.0% |
| 营业利润率 | -25.6% | -1.8% |
| 净利率 | -29.5% | -1.2% |
| 营收同比 | -5.9% | -3.0% |
| 净利润同比 | -62.2% | 76.4% |
| 每股收益（稀释后） | $-0.40 | $-0.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSUDMY
| Q4 25 | $199.9M | $194.0M | ||
| Q3 25 | $458.6M | $195.7M | ||
| Q2 25 | $178.5M | $199.9M | ||
| Q1 25 | $166.8M | $200.3M | ||
| Q4 24 | $212.5M | $199.9M | ||
| Q3 24 | $196.8M | $195.4M | ||
| Q2 24 | $199.7M | $194.4M | ||
| Q1 24 | $172.3M | $196.8M |
净利润APLSUDMY
| Q4 25 | $-59.0M | $-2.3M | ||
| Q3 25 | $215.7M | $1.6M | ||
| Q2 25 | $-42.2M | $6.3M | ||
| Q1 25 | $-92.2M | $-1.8M | ||
| Q4 24 | $-36.4M | $-9.9M | ||
| Q3 24 | $-57.4M | $-25.3M | ||
| Q2 24 | $-37.7M | $-31.8M | ||
| Q1 24 | $-66.4M | $-18.3M |
毛利率APLSUDMY
| Q4 25 | — | 66.0% | ||
| Q3 25 | — | 65.9% | ||
| Q2 25 | — | 66.1% | ||
| Q1 25 | — | 64.6% | ||
| Q4 24 | — | 63.6% | ||
| Q3 24 | — | 63.0% | ||
| Q2 24 | — | 62.3% | ||
| Q1 24 | — | 61.2% |
营业利润率APLSUDMY
| Q4 25 | -25.6% | -1.8% | ||
| Q3 25 | 48.7% | -0.1% | ||
| Q2 25 | -18.6% | 2.0% | ||
| Q1 25 | -50.0% | -2.2% | ||
| Q4 24 | -12.3% | -5.8% | ||
| Q3 24 | -24.0% | -15.1% | ||
| Q2 24 | -14.7% | -13.1% | ||
| Q1 24 | -36.0% | -11.5% |
净利率APLSUDMY
| Q4 25 | -29.5% | -1.2% | ||
| Q3 25 | 47.0% | 0.8% | ||
| Q2 25 | -23.6% | 3.1% | ||
| Q1 25 | -55.3% | -0.9% | ||
| Q4 24 | -17.1% | -4.9% | ||
| Q3 24 | -29.2% | -12.9% | ||
| Q2 24 | -18.9% | -16.4% | ||
| Q1 24 | -38.5% | -9.3% |
每股收益（稀释后）APLSUDMY
| Q4 25 | $-0.40 | $-0.01 | ||
| Q3 25 | $1.67 | $0.01 | ||
| Q2 25 | $-0.33 | $0.04 | ||
| Q1 25 | $-0.74 | $-0.01 | ||
| Q4 24 | $-0.30 | $-0.06 | ||
| Q3 24 | $-0.46 | $-0.17 | ||
| Q2 24 | $-0.30 | $-0.21 | ||
| Q1 24 | $-0.54 | $-0.12 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $358.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $210.5M |
| 总资产 | $1.1B | $617.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSUDMY
| Q4 25 | $466.2M | $358.7M | ||
| Q3 25 | $479.2M | $371.2M | ||
| Q2 25 | $370.0M | $392.0M | ||
| Q1 25 | $358.4M | $357.0M | ||
| Q4 24 | $411.3M | $354.4M | ||
| Q3 24 | $396.9M | $357.1M | ||
| Q2 24 | $360.1M | $420.9M | ||
| Q1 24 | $325.9M | $430.7M |
总债务APLSUDMY
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSUDMY
| Q4 25 | $370.1M | $210.5M | ||
| Q3 25 | $401.2M | $221.8M | ||
| Q2 25 | $156.3M | $233.4M | ||
| Q1 25 | $164.2M | $209.4M | ||
| Q4 24 | $228.5M | $197.4M | ||
| Q3 24 | $237.1M | $196.3M | ||
| Q2 24 | $264.3M | $252.3M | ||
| Q1 24 | $266.7M | $296.5M |
总资产APLSUDMY
| Q4 25 | $1.1B | $617.7M | ||
| Q3 25 | $1.1B | $618.9M | ||
| Q2 25 | $821.4M | $644.0M | ||
| Q1 25 | $807.3M | $639.0M | ||
| Q4 24 | $885.1M | $605.6M | ||
| Q3 24 | $901.9M | $608.9M | ||
| Q2 24 | $904.5M | $671.9M | ||
| Q1 24 | $831.9M | $708.5M |
负债/权益比APLSUDMY
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $15.5M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $15.0M |
| 自由现金流率自由现金流/营收 | -7.1% | 7.7% |
| 资本支出强度资本支出/营收 | 0.1% | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $81.9M |
8季度趋势，按日历期对齐
经营现金流APLSUDMY
| Q4 25 | $-14.2M | $15.5M | ||
| Q3 25 | $108.5M | $15.7M | ||
| Q2 25 | $4.4M | $44.2M | ||
| Q1 25 | $-53.4M | $12.2M | ||
| Q4 24 | $19.4M | $9.6M | ||
| Q3 24 | $34.1M | $-6.1M | ||
| Q2 24 | $-8.3M | $28.6M | ||
| Q1 24 | $-133.0M | $21.0M |
自由现金流APLSUDMY
| Q4 25 | $-14.3M | $15.0M | ||
| Q3 25 | $108.3M | $15.1M | ||
| Q2 25 | $4.4M | $41.9M | ||
| Q1 25 | $-53.4M | $9.8M | ||
| Q4 24 | $19.3M | $8.4M | ||
| Q3 24 | — | $-6.7M | ||
| Q2 24 | $-8.4M | $28.2M | ||
| Q1 24 | $-133.3M | $20.8M |
自由现金流率APLSUDMY
| Q4 25 | -7.1% | 7.7% | ||
| Q3 25 | 23.6% | 7.7% | ||
| Q2 25 | 2.5% | 21.0% | ||
| Q1 25 | -32.0% | 4.9% | ||
| Q4 24 | 9.1% | 4.2% | ||
| Q3 24 | — | -3.4% | ||
| Q2 24 | -4.2% | 14.5% | ||
| Q1 24 | -77.3% | 10.6% |
资本支出强度APLSUDMY
| Q4 25 | 0.1% | 0.3% | ||
| Q3 25 | 0.0% | 0.3% | ||
| Q2 25 | 0.0% | 1.1% | ||
| Q1 25 | 0.0% | 1.2% | ||
| Q4 24 | 0.0% | 0.6% | ||
| Q3 24 | 0.0% | 0.3% | ||
| Q2 24 | 0.0% | 0.2% | ||
| Q1 24 | 0.2% | 0.1% |
现金转化率APLSUDMY
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | 9.58× | ||
| Q2 25 | — | 7.06× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
UDMY
暂无分部数据
